Full-Time
Confirmed live in the last 24 hours
Develops cell therapy for chronic kidney disease
Senior
Winston-Salem, NC, USA
ProKidney focuses on developing a new treatment for Chronic Kidney Disease (CKD) using a cell therapy called rilparencel. This therapy aims to help preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which is often the only option for these patients. ProKidney is currently in the late stages of clinical trials, and early results indicate that rilparencel may effectively maintain kidney function. What sets ProKidney apart from its competitors is its specific focus on CKD and its unique approach to treatment through cell therapy, targeting a significant and underserved patient population. The company's goal is to provide a groundbreaking alternative to dialysis, improving the quality of life for millions of CKD patients. Once rilparencel receives regulatory approval, ProKidney plans to sell and distribute the therapy to healthcare providers and patients, ensuring broad access to this important treatment.
Company Stage
IPO
Total Funding
$559.3M
Headquarters
Winston-Salem, North Carolina
Founded
2015
Help us improve and share your feedback! Did you find this helpful?